2018
DOI: 10.1080/14737159.2018.1427068
|View full text |Cite
|
Sign up to set email alerts
|

CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer

Abstract: Introduction: Prostate cancer is a highly heterogeneous disease, with remarkably different prognosis across all stages. Increased circulating tumor cell (CTC) count (≥ 5) using the CellSearch assay has been identified as one of the markers that can be used to predict surv Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

3
46
0
1

Year Published

2018
2018
2022
2022

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 57 publications
(51 citation statements)
references
References 67 publications
3
46
0
1
Order By: Relevance
“…Several different blood-based AR-V7 detection assays are available, including CTC-based protein immunofluorescence and mRNA-based assays that can be performed using CTCs, whole-blood RNA, and plasma-derived exosomes [16,20]. Furthermore, different detection technologies are [11][12][13][14][15][21][22][23][24][25][26][27].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Several different blood-based AR-V7 detection assays are available, including CTC-based protein immunofluorescence and mRNA-based assays that can be performed using CTCs, whole-blood RNA, and plasma-derived exosomes [16,20]. Furthermore, different detection technologies are [11][12][13][14][15][21][22][23][24][25][26][27].…”
Section: Discussionmentioning
confidence: 99%
“…These findings suggest that AR-V7 may serve as a predictive biomarker of the lack of response to ARS inhibitors. The prevalence of AR-V7 in men with mCRPC increases with increasing lines of treatment and depends on the assay used [16]. Furthermore, the impact of minimal AR-V7 expression on clinical outcomes following ARS-inhibitor treatment remains unclear.…”
mentioning
confidence: 99%
“…Moreover, AR-V7-positive CTCs are associated with worse PSA response rates and shorter progression-free and overall survival rates. Therefore, AR-V7 may be promising for a potential target of diagnosis, prognosis and therapy in metastatic CRPC [69][70][71]. The full-length AR protein is encoded by AR isoform composed of eight exons and consists of four core domains: The N-terminal domain (NTD), the DNA binding domain (DBD), the hinge region and the C-terminal ligand binding domain (LBD).…”
Section: Psfmentioning
confidence: 99%
“…However, many patients of PCa were diagnosed at a very late stage and their survival rate reduced drastically, due to no obvious symptoms apart from those of urinary tract infection (2). Currently the main and standard treatment is androgen deprivation therapy (ADT) because of the irreplaceable role of androgen receptor (AR) in progression of PCa (3,4). ADT mainly include medical castration and surgical castration, but most patients nally progressed to castration-resistant prostate cancer (CRPC), even metastasis castration resistant prostate cancer (mCRPC) with no effective treatment (5,6).…”
Section: Introductionmentioning
confidence: 99%